Juno Therapeutics, Inc. (NASDAQ:JUNO) Position Maintained by Sib LLC
Sib LLC maintained its stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 100,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Juno Therapeutics comprises approximately 2.3% of Sib LLC’s investment portfolio, making the stock its 14th largest position. Sib LLC owned 0.10% of Juno Therapeutics worth $2,989,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the company. Teachers Advisors LLC raised its stake in Juno Therapeutics by 5.8% in the first quarter. Teachers Advisors LLC now owns 64,365 shares of the biopharmaceutical company’s stock worth $1,428,000 after buying an additional 3,531 shares during the period. Great West Life Assurance Co. Can raised its stake in Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the period. Opus Point Partners Management LLC raised its position in shares of Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock valued at $216,000 after buying an additional 4,560 shares during the last quarter. Baird Financial Group Inc. raised its position in shares of Juno Therapeutics by 25.7% in the first quarter. Baird Financial Group Inc. now owns 28,583 shares of the biopharmaceutical company’s stock valued at $634,000 after buying an additional 5,839 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Juno Therapeutics by 11.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 67,000 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 7,137 shares during the last quarter. Institutional investors own 64.51% of the company’s stock.
Shares of Juno Therapeutics, Inc. (JUNO) traded up 2.79% during mid-day trading on Friday, hitting $29.88. The stock had a trading volume of 1,898,914 shares. Juno Therapeutics, Inc. has a 12-month low of $17.52 and a 12-month high of $35.04. The company’s 50 day moving average price is $27.95 and its 200 day moving average price is $24.15. The stock’s market cap is $3.11 billion.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 26.26%. The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the prior year, the firm earned ($0.64) earnings per share. The firm’s quarterly revenue was down 22.8% on a year-over-year basis. Equities research analysts predict that Juno Therapeutics, Inc. will post ($2.98) EPS for the current fiscal year.
WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/07/sib-llc-has-2989000-position-in-juno-therapeutics-inc-nasdaqjuno-updated-updated-updated.html.
Several brokerages recently weighed in on JUNO. Vetr upgraded Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 price objective for the company in a research report on Monday, July 31st. Wedbush reiterated a “neutral” rating and issued a $24.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, June 6th. BidaskClub lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. Zacks Investment Research lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, BTIG Research lowered Juno Therapeutics from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $12.00 to $23.00 in a research report on Tuesday, June 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $30.81.
In other Juno Therapeutics news, Director Anthony B. Evnin purchased 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The stock was purchased at an average cost of $24.40 per share, with a total value of $219,600.00. Following the transaction, the director now owns 66,301 shares in the company, valued at $1,617,744.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the company’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,041,500 shares of company stock valued at $217,230,360. 15.26% of the stock is owned by corporate insiders.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Stock Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related stocks with our FREE daily email newsletter.